🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Zoetis Inc. ZTS SPX

Healthcare · Drug Manufacturers - Specialty & Generic · United States
https://www.zoetis.com
Company Profile ↓
$74.53
-51.37% 1Y
Mkt Cap$31.25B
P/E12.22
P/B9.50
Div. Yield2.83%
52W High$154.88
52W Low$71.86
Book Value$7.84
EPS (TTM)$6.10

Company Overview

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 67.7%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 27.1%.

Reasonable Valuation

Trades at a P/E of 12.2, below the sector median of 25.9.

Healthy Margins

Maintains a net profit margin of 28.0%.

Dividend Income

Offers a dividend yield of 2.83%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $9.47B (+2.3% YoY); net profit $2.67B.
  • Trailing 12 Months Year-on-year growth — revenue +2.9%, earnings +6.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR 5.4%, profit CAGR 8.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:5.42%
1 Year:2.90%

Compounded Profit Growth

5 Years:8.13%
1 Year:6.00%

Stock Price Performance

1 Year:-51.37%
6 Months:-40.01%
3 Months:-38.19%
1 Month:-6.33%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 3% of range
$71.86 $154.88
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)40.35 · Neutral
Price Performance
1M-6.33%
3M-38.19%
6M-40.01%
1Y-51.37%
Valuation vs Sector

P/E of 12.22 is below the sector median of 25.88 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 67.7%.
  • Healthy ROCE of 27.1%.
  • Excellent profit margin of 28.0%.
  • Attractive dividend yield of 2.83%.
  • Generates positive free cash flow.

CONS

  • Trading 51.9% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
12.22
Industry PE
25.88
Forward P/E
10.08
PEG Ratio
1.79
Book Value
$7.84
Price to Book
9.50
P/S
3.28
EV/EBITDA
9.49
Dividend Yield
2.83%

Growth (CAGR)

Revenue 5Y
5.42%
Profit 5Y
8.13%
Revenue (YoY)
2.90%
Earnings (YoY)
6.00%

Profitability & Returns

ROCE
27.07%
ROE
67.75%
ROA
15.53%
Profit Margin
28.04%
Op Margin
36.56%
Gross Margin
71.84%
EPS (Latest Qtr)
$1.42
EPS (TTM)
$6.10

Balance Sheet & Liquidity

Debt/Equity
2.86
Quick Ratio
1.68
Current Ratio
3.15
Debt
$9.25B
Total Assets
$15.15B
Current Assets
$6.47B
Working Capital
$4.53B

Ownership

Promoter Holding
0.15%
Chg in Prom Hold
-0.00%
FII / Inst Holding
102.86%
Chg in FII Hold
-0.18%

Financial Snapshot

Enterprise Value
$31.25B
Total Revenue (TTM)
$9.53B
EBITDA
$4.07B
Free Cash Flow
$1.78B
Operating Cash Flow
$2.79B
Shares Outstanding
419.23M
Gross Margin
71.84%
Payout Ratio
33.28%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ZTS Zoetis Inc. SPX 74.53 12.22 $31.25B 2.83% 27.07% 67.75% 5.42% 8.13%
2 LLY Eli Lilly and Company SPX 1,156.63 41.13 $1.03T 0.60% - 107.46% 7.20% 11.41%
3 JNJ Johnson & Johnson SPX 247.02 28.66 $594.63B 2.23% 14.88% 26.42% 2.43% 4.76%
4 ABBV AbbVie Inc. SPX 244.11 119.08 $431.29B 3.04% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPX 418.52 31.54 $380.08B 2.18% 9.74% 12.18% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPX 123.61 34.82 $305.29B 2.82% - 18.94% 5.64% 10.01%
7 AZN AstraZeneca PLC NDX 168.37 26.10 $261.12B 1.87% 15.97% 23.48% 9.82% 45.96%
8 TMO Thermo Fisher Scientific Inc. SPX 535.29 29.40 $198.93B 0.35% 8.14% 13.52% 8.81% 12.95%
9 AMGN Amgen Inc. NDXSPX 358.32 24.92 $193.39B 2.80% 18.02% 101.32% 11.77% 5.58%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2015Sep 2015Dec 2015Apr 2016Jul 2016Oct 2016Dec 2016Apr 2017Jul 2017Oct 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -------1.23B1.27B1.35B1.46B1.37B1.42B1.48B1.56B1.46B1.55B1.58B1.67B1.53B1.55B1.79B1.87B1.95B1.99B1.99B2.05B2.00B2.00B2.18B2.15B2.19B2.36B2.39B-2.20B2.46B2.40B2.39B2.26B
Cost of Revenue -----------------------------------618.00M649.00M683.00M712.00M641.00M
Gross Profit -----------------------------------1.58B1.81B1.72B1.68B1.62B
Operating Expenses -----------------------------------768.00M822.00M781.00M849.00M799.00M
Operating Income -----------------------------------812.00M989.00M936.00M826.00M822.00M
EBITDA -----------------------------------946.00M1.08B1.07B939.00M939.00M
Interest Expense -----------------------------------54.00M53.00M58.00M57.00M62.00M
Pretax Income -----------------------------------773.00M902.00M887.00M761.00M758.00M
Tax Provision -----------------------------------171.00M184.00M166.00M158.00M157.00M
Net Income -37.00M189.00M22.00M204.00M224.00M239.00M154.00M238.00M247.00M298.00M81.00M352.00M384.00M347.00M345.00M312.00M371.00M433.00M384.00M423.00M377.00M479.00M559.00M512.00M552.00M595.00M529.00M529.00M552.00M671.00M596.00M599.00M624.00M682.00M-602.00M718.00M721.00M603.00M601.00M
Diluted EPS -0.070.380.040.410.450.480.310.480.500.610.160.720.790.710.710.650.770.900.800.880.791.001.171.071.161.261.121.131.191.451.291.311.371.50-1.411.611.631.371.42

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 4.23B4.34B4.56B4.79B4.76B4.89B5.31B5.83B6.26B6.67B7.78B8.08B8.54B9.26B9.47B
Cost of Revenue -----------2.45B2.56B2.72B2.67B
Gross Profit -----------5.63B5.98B6.54B6.80B
Operating Expenses -----------2.70B2.91B3.15B3.20B
Operating Income -----------2.93B3.07B3.39B3.60B
EBITDA -----------3.34B3.67B3.85B4.07B
Interest Expense -----------221.00M239.00M225.00M222.00M
Pretax Income -----------2.66B2.94B3.13B3.36B
Tax Provision -----------545.00M596.00M637.00M687.00M
Net Income 245.00M436.00M504.00M583.00M339.00M821.00M864.00M1.43B1.50B1.64B2.04B2.11B2.34B2.49B2.67B
Diluted EPS 0.490.871.011.160.681.651.752.933.113.424.274.495.075.476.02

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --6.26B6.56B6.59B7.91B7.65B8.59B10.78B11.54B13.61B-14.93B14.29B14.24B15.47B
Current Assets ------------7.51B6.34B5.99B6.77B
Cash & Equivalents 63.00M79.00M317.00M610.00M882.00M1.15B727.00M1.56B----3.58B2.04B1.99B2.31B
Inventory ------------2.35B2.56B2.31B2.43B
Receivables ------------1.22B1.30B1.32B1.59B
Total Liabilities --2.22B5.60B5.25B6.82B6.15B6.80B8.59B8.84B9.84B-10.52B9.29B9.47B12.14B
Current Liabilities --1.12B1.42B1.09B1.78B1.12B1.09B1.22B1.81B2.17B-3.17B1.89B3.41B2.23B
Long Term Debt --03.64B3.62B4.46B4.47B4.95B6.44B5.95B6.59B-6.55B6.56B5.22B9.04B
Total Debt ------------8.09B6.75B6.74B9.24B
Total Equity 3.34B3.74B4.03B940.00M1.31B1.07B1.49B1.77B2.19B2.71B3.77B-4.41B5.00B4.77B3.33B
Shares Outstanding ------------501.89M501.89M501.89M501.89M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 497.00M454.00M681.00M626.00M664.00M713.00M1.35B1.79B1.79B2.13B-1.91B2.35B2.95B2.90B
Investing Cash Flow -449.00M-135.00M-179.00M-187.00M-1.11B-214.00M-270.00M-2.26B-504.00M-572.00M--883.00M-777.00M-315.00M-748.00M
Financing Cash Flow -30.00M-78.00M-200.00M-154.00M755.00M-903.00M-251.00M533.00M-951.00M123.00M--904.00M-3.11B-2.66B-1.87B
Capital Expenditure -135.00M-126.00M-184.00M-180.00M-224.00M-216.00M-224.00M-338.00M-460.00M-453.00M--586.00M-732.00M-655.00M-621.00M
Free Cash Flow 362.00M328.00M497.00M446.00M440.00M497.00M1.12B1.45B1.33B1.67B-1.33B1.62B2.30B2.28B
Net Change in Cash -----------125.00M-1.53B-22.00M286.00M
Share Buybacks --00203.00M300.00M500.00M698.00M626.00M250.00M743.00M1.59B1.09B1.86B3.23B

Ratios (Annual)

Figures in %.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -----------69.6%70.0%70.6%71.8%
Operating Margin % -----------36.2%35.9%36.6%38.0%
Net Margin % 5.8%10.1%11.1%12.2%7.1%16.8%16.3%24.5%24.0%24.5%26.2%26.2%27.4%26.9%28.2%
ROE % 6.6%10.8%53.6%44.5%31.7%55.2%48.8%65.4%55.4%43.5%-48.0%46.9%52.1%80.2%
ROCE % -----------24.9%24.8%31.3%27.2%

Shareholding Pattern

Insiders
0.15%
Institutions
102.86%
Public Float
103.02%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 8.49% 35.58M $2.65B
2 Vanguard Capital Management LLC 6.22% 26.07M $1.94B
3 Vanguard Portfolio Management LLC 5.72% 23.97M $1.79B
4 State Street Corporation 4.61% 19.32M $1.44B
5 State Farm Mutual Automobile Insurance Co 3.79% 15.89M $1.18B
6 Morgan Stanley 3.37% 14.15M $1.05B
7 Geode Capital Management, LLC 2.71% 11.35M $845.86M
8 Wellington Management Group, LLP 2.42% 10.15M $756.49M
9 Nordea Investment Management AB 1.40% 5.87M $437.13M
10 Northern Trust Corporation 1.32% 5.55M $413.35M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ZTS

Google News ue, 14 Jul 2026

Zoetis (ZTS) Stock Dips While Market Gains: Key Facts - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNWUJsZ3Z2aEJzYWh6Vk1neDIzNld3RHB0Nk5ESV9WYWZMUTNYZUpXWFRwZ2RtRE0wc3dWLW1fTDI3LXZtbHdZaDFXc2h2cGZ0eXdmM21mZjBzeVpYb0pPQTh3WDdabEg4T2RueUNIUDM4M3VwRExSRV9JaGFFdGFIaTN5MHVIRTJUMVZ5M2…

Google News Wed, 15 Jul 2026

Levi & Korsinsky Reminds Zoetis Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 27, 2026 - ZTS - Morningstar

<a href="https://news.google.com/rss/articles/CBMimwJBVV95cUxPYk8tX1NURDV0djgtSGRyU1pMai1pQXdiN2psaEhXay1odDQ2bWk1QkRncDdIMkVKX3BXWjJxMk1UVkFVTXBqMHFPUmxRS2hoRllnVldvcE1OeENHdjFXVXlpdWlYS2d3QUxJc0xIVFNxNDh1SFk2YmlZV1ZtSHZTdHpveUp1TjBOWUhLc3…

Google News Wed, 15 Jul 2026

Here's What We Like About Zoetis' (NYSE:ZTS) Upcoming Dividend - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxPelRkRmM2QjRHVnhrTjFLNUtCLXE0LWVBbF9peWNuNnNfV0xONzl1ZEktQV9XM2F5QkNlQXFJUHdnMUFBQjJmWnhEVG9OV0JuWmNwLWpiZ09UT3B3RzMwUjZTalpKMFRoM205M1ZrQjNiNzJmMmNZTkJCcGtuMm9QTFJlYmcySkdqMHJQV2…

Google News Wed, 15 Jul 2026

One injection may give dogs with osteoarthritis up to 3 months’ relief - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQaXBqanNHdUVYYnc4S0ZVRTktNW9wOUU0aTNzRERGVFoyYTl3OV8wbUxCV2hybzBRd1hySUxPV096RVpMUWRscmRsbUcxOXBRNnpPV0RVaDliSkJvblNXOU1vMDdhbmtCLXlKeUFPOWdnY3dCZk1NX21zNzRHdnYteGhLYXBtcWpoNi1CNU…

Google News Wed, 15 Jul 2026

Fifth Third Bancorp Purchases 68,180 Shares of Zoetis Inc. $ZTS - MarketBeat

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNenRiMnktZlRlVGNIaDlBVXR6OEpLRVBrbnZRcUtpdU5BNEhiN255dklnYjZ2b0dIRzBtbTYxZGlRZDNFX2RDS2VnMmFKSWJROVcySzd2OFB2cHJ3MGVyelMwV1FKNGptZldzRFJnS0xuLWItaTJDRnpkNnphczlWQmxRREc5MktmTV8tZz…

Google News Wed, 15 Jul 2026

Zoetis Launches Lenivia for Osteoarthritis Pain Management (ZTS) - GuruFocus

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQaXBNelFLSVJOSEtPZi11N2FTMjVpZFotUExCQU5BclR3bXpfRUd4b3VyN2dMM0lKLXRGMkQ5WHY5T29TTS1KRVRzZlRVQnJtTVdVODZhNTZ4Rm9qeTBNaEJnaXZBaW9tMmpVSERhRTY2T0JJZGsxN2lqbS11M09KOWc3bUZ3RWdzTkhKcE…

ZTS — Frequently Asked Questions

What is the current share price of Zoetis Inc. (ZTS)?

As of 2026-07-15 16:51 PDT, Zoetis Inc. (ZTS) trades at $74.53 on NYSE. Its 52-week range is $71.86 to $154.88.

What is the market capitalisation of ZTS?

Zoetis Inc. (ZTS) has a market capitalisation of $31.25B on NYSE.

What is the P/E ratio of ZTS?

ZTS trades at a trailing price-to-earnings (P/E) ratio of 12.22. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 9.50.

Does ZTS pay a dividend?

Zoetis Inc. (ZTS) currently offers a dividend yield of 2.83%.

What is the return on equity (ROE) of ZTS?

ZTS has a return on equity (ROE) of 67.75%. Its return on capital employed (ROCE) is 27.07%.

Is ZTS a good stock to buy?

This page provides a data-driven analysis of Zoetis Inc. (ZTS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space